HealthcareAI Research4 min reading time

Boehringer Ingelheim Licenses Owkin’s K Pro AI Scientist and Patient Data

Unite.AI
Read full post
Owkin has licensed its AI Scientist platform K Pro and multimodal oncology and immunology patient data to Boehringer Ingelheim to accelerate biopharma research. The deal builds on a 2025 pilot using Owkin's MOSAIC spatial multiomics cancer dataset. Boehringer's teams will use K Pro to analyze data and generate hypotheses in oncology and immunology research.

More in Healthcare

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources
Healthcare5 min read

​Digital Finance Needs A New Kind Of Identity For AI-Driven Economies

Forbes

How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules

Open AI News